Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 1069-1074

  Klepser, Michael E ^a   Patel, Kalpana B ^a   Nicolau, David P ^a   Quintiliani, Richard ^a   Nightingale, Charles H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0031702762     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Geraci JE, Heilman FR, Nichols DR, et al. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute microbial endocarditis. Staff Meet Mayo Clin 1958;33:172-81.
2. Geraci JE, Heilman FR. Vancomycin in the treatment of staphylococcal endocarditis. Staff Meet Mayo Clin 1960;35: 316-27.
3. Duffull SB, Begg EJ Chambers ST, Barclay ML. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 1994;38:2480-2.
4. Rybak MJ, Cappelletty DM, Ruffing MJ, et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.
5. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15:85-91.
6. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996;40: 696-700.
7. National Committee for Clinical and Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. Villanova, PA: Author, 1993.
8. National Committee for Clinical and Laboratory Standards. Methodology for the serum bactericidal test. Tentative guideline M21-T. Villanova, PA: Author, 1993.
9. Patel KB, Marangos MN, Nicolau DP, Nightingale CH. Synergistic activity of vancomycin or teicoplanin combined with streptomycin against VanB-type resistant enterococci with variable levels of vancomycin-resistance. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4-7, 1994.